Oxigénio Medicinal Air Liquide Medicinal (Oxygen)

Oxygen, the active ingredient in Oxigénio Medicinal Air Liquide Medicinal, is a medical gas presented as a medicinal gas for inhalation use. It provides supplemental oxygen therapy for patients with respiratory compromise, supporting oxygen saturation in acute and chronic settings. GNH USA supplies Oxigénio Medicinal Air Liquide Medicinal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Oxigénio Medicinal Air Liquide Medicinal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Oxigénio Medicinal is a medical gas used in respiratory support and oxygen therapy pathways.

- Acute hypoxemia: improves arterial oxygen levels in emergency and intensive care settings. - Chronic obstructive pulmonary disease (COPD): helps maintain adequate oxygen saturation during daily activities. - Post‑operative recovery: supports tissue oxygenation after surgery to aid healing. - Carbon‑dioxide retention syndromes: provides a high‑fraction oxygen mixture to reduce respiratory drive. - High‑altitude exposure: prevents hypoxic symptoms in individuals ascending to high elevations.

Oxygen therapy is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasal dryness or irritation. - Cough or mild throat discomfort. - Headache, especially with high flow rates. - Light‑headedness or dizziness. - Mild fatigue.

Serious or Rare Side Effects: - Pulmonary oxygen toxicity leading to atelectasis. - Retinal damage in premature infants (retinopathy of prematurity). - Fire hazard when used near open flames. - Hypercapnia in patients with COPD who retain CO₂. - Severe bronchospasm. - Hypoxemia rebound after abrupt discontinuation.

Oxygen should be administered only under appropriate clinical supervision.

- Assess patient: verify indication and baseline oxygen saturation before initiating therapy. - Monitor continuously: use pulse oximetry or arterial blood gas analysis to guide flow adjustments. - Avoid excessive concentration: maintain the lowest effective FiO₂ to reduce toxicity risk. - Contraindications: do not use in patients with untreated pneumothorax. - Fire safety: keep away from smoking materials and open flames. - Store at ambient temperature: keep cylinders in a well‑ventilated, upright position, protected from heat and direct sunlight.

Oxygen can modify the effectiveness or safety profile of several concurrent therapies.

Major Interactions (Avoid): - Flammable anesthetic agents: increased fire risk when combined with high‑flow oxygen. - Nitric oxide therapy: can reduce the efficacy of inhaled NO.

Moderate Interactions (Monitor Closely): - Sedatives and opioids: may deepen respiratory depression if oxygen levels are insufficient. - Chemotherapy agents (e.g., bleomycin): higher oxygen concentrations can exacerbate pulmonary toxicity. - Antioxidant supplements: theoretical risk of altered oxidative balance, monitor patient response.